Related Experiment Videos
Proliferative activity in benign and neoplastic prostatic epithelium
1Research Service, Department of Veterans Affairs Medical Center, MN 55417.
The Journal of Pathology
|November 1, 1994
Summary
Evaluating prostate cancer proliferation using bromodeoxyuridine (BrdU), Ki67, and PCNA reveals significant variability. BrdU indices over 10 per mile predict extracapsular extension, aiding prognosis for unpredictable grade 7 cancers.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Early prostate cancer detection necessitates improved prognostic criteria.
- Understanding factors influencing prostate cancer progression remains a challenge.
- Proliferative activity is a key area of investigation with conflicting findings.
Purpose of the Study:
- To evaluate proliferative activity in benign and neoplastic prostatic epithelium.
- To analyze methodological variability in proliferation assessment.
- To determine if proliferation indices complement histological grading for clinical utility.
Main Methods:
- Studied 88 prostate cancer and 46 benign prostatic pathology samples.
- Assessed proliferative activity using in vitro bromodeoxyuridine (BrdU) incorporation.
- Utilized Ki67 and proliferating cell nuclear antigen (PCNA) as markers.
Main Results:
- Increased proliferation observed in inflammation and metaplasia, but not hyperplasia.
- Prostate cancers exhibited marked variability in proliferation indices.
- Bromodeoxyuridine indices >10 per mile showed 79% positive predictive value for extracapsular extension.
Conclusions:
- Proliferative capacity assessment offers clinical value beyond histological grading.
- Bromodeoxyuridine indices may aid in evaluating unpredictable grade 7 prostate cancers.
- Methodological choice impacts proliferation assessment and clinical correlation.